OncoSec Medical Incorporated
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCSQ research report →
Companyoncosec.com
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma.
- IPO
- 2010
- Employees
- 40
- HQ
- Pennington, NJ, US
Price Chart
Valuation
- Market Cap
- $596
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -154.68%
- ROIC
- -195.00%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-34,179,634 · 24.33%
- EPS
- $-19.13 · 36.66%
- Op Income
- $-37,012,062
- FCF YoY
- 23.97%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 9.96
- Avg Volume
- 60.43K
Get TickerSpark's AI analysis on ONCSQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ONCSQ Coverage
We haven't published any research on ONCSQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ONCSQ Report →